Orioles ‘Zill Billy’ usher is Swinging at Lung Cancer

August 17th, 2013

BALTIMORE (WMAR) – The familiar sounds of John Denver’s “Thank God I’m a Country Boy” during the 7 th inning stretch at Camden Yards brought Charlie Zill front and center to entertain fans as his character, Zill Billy.
“I was playing around one game and put in the teeth,” he said. “I had on a pair of suspenders and turned my hat sideways. I started dancing around, and people seemed to like it.”

An usher at Camden Yards for 17 seasons, Zill followed his passion for the Orioles that dated back to days spent at games with his uncle.
“He was like a mentor to me,” Zill said. “Ever since then, I wanted to work for the Orioles.”
Zill got that chance in 1996, quickly becoming a favorite around the yard. “It’s a privilege to work for the orioles,” he said.
Then, in 1998, after a little coaxing from fans, the Zill Billy was born.

“I’d never have done this if it wasn’t for them,” Zill said. “They created me and got me to do this.”
Zill kept the tradition going season after season, adding new steps and costume pieces along the way. “Each season, I tried to add something to make it better.”

Then in 2009, his life took a dramatic and irreversible turn.
“I had a chronic cough and went to the doctor. That’s when they told me I had lung cancer,” he said.
It was stage four cancer that came with a grim prognosis. “They gave me a year to live when I was diagnosed,” he said.
That was four years ago. In that time, Zill decided to keep dancing and thrilling the crowd as long as his body would let him.
“I believe my working for the o’s was medicine for me,” he said, fighting back tears. “Getting out there, doing my thing… I believe it helped. It helped me a lot.”

Eventually, the effects of the cancer proved too much, and last season during game two of the ALDS at Camden Yards, the Zill Billy knew it was time to give fans his last dance.
“I remember being so weak,” he said. “I didn’t think I was going to be able to do it, but God gave me the will power to go on.”
Today, in Red Lion, Penn., 60 miles from Baltimore, the rhythm of chimes, dancing on a windy morning, replaces the hum of the ballpark. Charlie Zill sits on a couch inside his red brick home tethered to an oxygen tank, fighting for every breath he has left.

“It’s hard for me to walk from here to the bathroom, and I’m out of breath, even with oxygen on,” he said.
He’s physically unable to return to Camden Yards now, but he’s not yet ready to throw in the towel. “I try to keep hope,” he said. “That’s the best thing to keep.”

He’s hoping for the outside chance of a cure and maybe one more trip to the ball park. He won’t be going there to work. This time, he gets to be the fan.

“I’m going to try. I don’t know,” he said. “Only the Lord knows, and I’ll let the spirits move me.”
If you’d like to send cards or letters Charlie Zill, you can send them to:
P.O. Box 604
Red Lion, PA 17356

Read more: http://www.abc2news.com/dpp/sports/baseball/orioles/orioles-zill-billy-usher-has-last-dance-battles-stage-four-cancer#ixzz2cGj9cBNy

Kathy Leiser: Changing the face of Lung Cancer

August 9th, 2013

Many people diagnosed with cancer ask “why me?” Kathy Leiser asks herself “what if?”
What if she hadn’t moved from Texas to Nashville to be closer to her two grown sons in 2009? What if she hadn’t heard that public service announcement about a Vanderbilt clinical trial looking for former smokers when she was headed to work that day? What if she, who spent most of her life caring for her family and let her own health care needs lapse, hadn’t picked up the phone to join the study?
She believes her guardian angels were looking out for her.

Leiser enrolled in the Nashville Lung Cancer Screening Trial with Pierre Massion, M.D., in 2011 to determine whether testing current and former smokers with a combination of bronchoscopy, CT scan, chest X-ray and pulmonary testing would result in the early detection of lung cancer.
“I didn’t think there was anything wrong with me,” said Leiser, a 63-year-old former smoker. “I had some shortness of breath but I wasn’t worried. As smokers, we are aware of the consequences of our actions. I just thought getting all those tests, and for free, was a good idea.”
Three days after testing, Massion called to say they found something and asked Leiser to come back in.

“I didn’t think it was going to be anything bad, bad. I don’t know why but I just didn’t,” said Leiser. “I took my son, Matt, with me because I knew he would remember things that I didn’t. Dr. Massion showed us my CT scan and up at the top of my right lung, there was a white spot.”
The spot was relatively small, only 2.8 centimeters, but Massion said he was 95 percent sure it was malignant. Next came a PET scan to determine if cancer was present anywhere else in her body, and the result was negative. After a consultation with thoracic surgeon Eric Grogan, M.D., MPH, Leiser underwent surgery to remove the Stage I nodule and the upper lobe of her right lung.
Four days later, she was released from the hospital and spent two tough months recovering at home, with her sons taking shifts to make sure their mother had round-the-clock care.

Today Leiser is cancer free, but she stops short of calling herself a cancer survivor.
“I got off easy, easy, easy compared to people that have to go through chemotherapy and radiation. Trying to hold onto a job while undergoing chemotherapy, now that’s a cancer survivor. I’m just someone who had surgery,” said Leiser.
Leiser takes ownership for her years of smoking, but cautions that smoking should not be used to stigmatize individuals and prevent them from seeking care. Smoking is not the only unhealthy behavior people engage in and lung cancer in never-smokers is still the sixth most common cause of cancer deaths in the country.

“I had a chest X-ray the year before my diagnosis, and no one saw anything,” said Leiser. “Without a CT scan, they never would have found it. That’s why I hope that a CT scan will become the standard of care, much like mammograms are for breast cancer and colonoscopies are for colon cancer.”

Lung cancer pill shows promise, CU patient is beating the odds

August 8th, 2013

DENVER — A lung cancer patient is beating the odds thanks to a new drug he’s receiving from doctors at the University of Colorado Anschutz Medical Campus.

Mark P. Marini is Changing the Face of Lung Cancer

July 27th, 2013

Thanks for selecting me as a Team Draft’s recipient as it was a special day for my wife and I and the owner of my company Anthony Cafaro Jr and his wonderful Gayle . I have been through quite a lot since my diagnosis in early June 2009. I’m a former smoker that quit in 1998 and became a fitness freak in 2001. I became passionate with running and took up competitive racing in both 5k’s and 10k’s at a local park in 2004 and was running about 30 races a year while running and training all year round . While on a six mile run after work with an attorney at my office, I thought that I felt good but on the way home I began to cough up fresh blood. I immediately went to my internist and following a week of testing team of doctors at the Cleveland Clinic, I was informed that I had lung cancer. My thoracic surgeon told me the next sixth months would be hell but I was in the best psychical condition of my life and I’m a type A personality with a great attitude so he told me I could beat this disease if I remained positive and upbeat . I did a split course treatment which was two “zaps” of radiation at 6:00 AM and 2:30, and then had chemotherapy on Mondays after radiation. Mondays were long as I left my house at 4:30 am and would return home at about 9:00PM. Luckily it was for only 12 treatments, but it was very exhausting . PS during those 12 days of treatment I ran about 4 miles at noon outside the Cleveland Clinic in between chemo and radiation treatments.

I then had surgery to remove my upper chamber of my left lung along with a portion of my lower lung. My thoracic surgeon prepared me by telling me it was the one of the most painful surgery’s known and he was not kidding. I got of the hospital in 5 days (normal stay was 6 to 8 days ) as I was determined to be normal . I was told most people take 2 months off on short term disability. I laughed when told that as I was working remote from my house about 10 days after my surgery. Although not moving very quickly I even walked a two mile fund raiser with my lovely wife about 16 days after my surgery. I was in the office about 16 days after my surgery.

After the surgery I had to finish up another round of radiation ( 2 weeks of double “zaps”) and chemotherapy for another three months . I’m proud to say, all while missing just a few days of work . I exercised 4 to 5 cardio sessions from the day I came home from my surgery also started weight lifting two times a week . And the reason I did all this was normalcy – most cancer patients just want to be normal and I was more determined than ever to make that happen !

I have been blessed by the following :1) a great support system in including my entire family but a special thanks to the following , my mother , my sisters, my sons and the true inspiration of my life my wife of 30 years as we have now been together 36 years. We met when I was I was a senior in high school and she was a freshman – she has been a rock thru this whole process and also our entire marriage 2) A great company that I work for called the Cafaro Company a private family owned by the same family since 1950 who gave me the greatest support and incredible medical coverage. The company owns and operates about 30,000, 000 square feet of mall and strip centers coast to coast 3 ) I was lucky and blessed to have one the top hospitals in the world a mere 60 miles from my home the world renowned Cleveland Clinic . My medical team consists of Dr Pennell oncologist, Dr Videdic radiologist, Dr Murthy thoracic surgeon, Dr Barnett neuro surgeon, and Dr Stevens neurologist. I termed them “the dream team of Doctors”. They were all so honest and compassionate with me which helped me thru the whole process.

Unfortunately the story doesn’t end there. I had three straight years of clean CT scans and my first of 2012 was clean back in March. I was losing some short memory and not finishing my thoughts so my Doctors wanted a MRI of my brain in late March. After a few tests, a malignant tumor was discovered on the left frontal lobe of my brain. I underwent brain surgery to remove the tumor and followed up with three weeks of radiation just to be safe. Again I missed about four days of work and was working remotely. I was back to work a couple of days later and traveling to a convention in Las Vegas only three weeks after my last radiation treatment (not really the brightest thing I ever did) .

The objective of this email is show you my plight and how with a great medical team, a great support system , and a great company I probably would not be here today writing this email . Again true special thanks to my wife , my “dream team” at the Clinic and not only the great Doctors but a staff from janitors , nurses, to physician assistants that are the best , most compassionate, well trained and positive employees in this country. Lastly to one the best organizations to work for in country the Cafaro Company in particular our Co President Anthony Cafaro Jr whose support, compassion, and caring nature are so heart felt and appreciated .

Now you can see how truly blessed that I am regardless what I have been through . My prognosis is very good and I have resumed full cardio activities, weight training at my gym about two months after my brain surgery. Yes I’m very lucky as I know that my faith and my God will always look over me and be there every step of the way .

I wake up every day which I consider a true blessing, Please feel free to pass this email along at either Chris Draft Foundation or the Cleveland Clinic. To all have great Holiday Season and Happy Healthy and Prosperous New Year. Hopefully I can meet Mr Draft thru my travels as it would be an honor to do so .

Mark Marini is Changing the Face of Lung cancer from TEAM DRAFT on Vimeo.


Not just a smoker’s disease — Former NFL player raises awareness for lung cancer

June 21st, 2013

Lung cancer is often perceived as a smoker’s disease. But a hard look at lung cancer diagnosis data reveals that 45 percent of patients with the disease are former smokers, and an additional 15 percent never smoked at all.

For Chris Draft, a former San Francisco 49ers linebacker who also played for the Stanford football team, this last statistic is all too real.

His wife, Keasha Draft, never smoked. She was 37 in December 2010 when she was diagnosed with Stage IV lung cancer. She died a year later, a month after she married Chris. According to the Chris Draft Family Foundation’s website, at the time of diagnosis, “her only ‘symptom’ was a slight shortness of breath a few days earlier.”

Typical symptoms of lung cancer are notoriously subtle and often do not appear until the late stages of the disease. They can range from a chronic cough to a slight shortness of breath or an ache in the back, chest or arm. As a result, only 16 percent of lung cancer patients are diagnosed when the cancer is still localized and easily treatable. There is also no current approved screening for early detection of lung cancer. This combination results in a devastatingly low the five-year survival rate.

According a National Cancer Institute study conducted from 1973 to 2008, the five-year survival rate for lung cancer is 16.3 percent—significantly lower than colon cancer (65.2 percent), breast cancer (90 percent), and prostate cancer (99 percent).

However, lung cancer research is also underfunded compared to these other cancers. According to a 2012 American Cancer Society study, lung cancer causes more deaths than the next three most fatal cancers—colon, cancer, and prostate—combined. However, it receives significantly less federal funding than the other three. Breast cancer alone received five times more federal funding than lung cancer in 2011, according to the Lung Cancer Foundation of America.

According to Draft, lung cancer research is underfunded because of the overemphasis on the link between the disease and smoking.

“All you see is a prevention message,” Draft said. “People think that guys who don’t smoke don’t get lung cancer.”

Draft and his wife launched Team Draft at their wedding in November 2011, hoping to use Keasha’s story to change the face of lung cancer, and to prevent it from being labeled a “smoker’s disease.”

Since Team Draft’s inception, Draft has visited over 80 medical centers nationwide.

“I wanted to find out what was being done, out there, in the field,” Draft said. “And who better to go to than the doctors?”

Draft is not only concerned with educating the public about the devastating effects of lung cancer, but also of the efforts being made to fight the disease. He says he hopes to motivate the public donate money and advocate for more lung cancer research.

“The key is hope,” Draft said emphatically. “With every cancer center that we’ve visited, there’s change. Changes, even changes that are small, are cause for hope.”

Last Tuesday, Draft visited Stanford Hospital. Prior to his visit, the medical center had never offered a tour of its newest lung cancer treatment facilities to anyone but government officials.

“We don’t do this for everyone, with this many physicians,” Whitney Greene, the service line administrator for the oncology department, said. “We did it for [Draft] because of his connection to Stanford and the 49ers, as well as his efforts to spread lung cancer awareness.”

Although the prognosis for lung cancer patients is still grim, new technology and treatment techniques have surfaced in disease research. Stanford Hospital is currently collaborating with the SLAC National Accelerator Laboratory, originally named Stanford Linear Accelerator Center, to devise the next line of linear accelerators machines to use in treating lung cancer.

The newest linear acceleration device, the Cyberknife, has the ability to track the tumor’s movement throughout the treatment procedure, while firing targeted radiation beams at the tumor. This device increases accuracy in comparison to previous radiation techniques, where tumors were not tracked during the treatment procedure.

The hospital has also made improvements in the patients’ comfort and quality of life. Among other developments, oral medication replaces certain treatments that require time in the hospital, and mesh face masks are now used in place of uncomfortable metal head-clamps that keep patients still while receiving treatment.

“Maybe [this campaign] can extend [a lung cancer patient's] life for two years more,” Draft said. “Some people think, oh, it’s only two years. But when you put it in perspective of your mom, your kids; it’s a different two years. Those two years are worth fighting for.”

Lung cancer remains a major killer

June 21st, 2013

By Kathryn Roethel of the SF Gate

The No. 1 killing cancer is not the one many people think of first. It’s not the one with the pink ribbon, or the one whose controversial screenings are grabbing headlines. It’s lung cancer. And even though it’s the third-most commonly diagnosed type, behind prostate and breast cancers, it claims more than twice as many lives annually than both of those – combined.

The majority of lung cancer patients are current or former smokers, but even non-smokers are at risk. And while survival rates have increased for many cancers over the last 40 years, the lung cancer five-year survival rate – 15 percent – hasn’t changed much. Symptoms don’t usually surface until the disease is in late stages, and even then they’re ambiguous – coughing, chest pain, weight loss and shortness of breath – so lung cancer is difficult to catch and treat early.

Researchers are trying to change that. Dr. Ann Leung, professor of radiology at Stanford, cites a recent New England Journal of Medicine study showing that a lung CT scan using a low dose of radiation could be a good screening option for some of the heaviest smokers. But the screening comes with risks of its own.

The numbers tell the story.

The percentage of lung cancer patients who have never smoked, according to the Lung Cancer Foundation of America.

The percentage of lung cancer patients who are former smokers. The remaining 40 percent are current smokers.

The number of “pack-years” New England Journal of Medicine researchers used to qualify someone as a heavy smoker with a high risk of lung cancer. If you smoke a pack (20 cigarettes) a day for one year, you’ve smoked one pack-year. To meet the 30 pack-year criteria, you could have smoked one pack a day, every day for 30 years, or two packs a day, every day for 15 years. If you meet this standard, researchers recommend talking to your doctor about having a CT scan to screen for lung cancer.

1 in 4
The ratio of heavy smokers in the study who had CT scans reveal potentially cancerous lung abnormalities. Upon further examination, about 95 percent of those abnormalities proved not to be cancer. Leung, who was not involved in the research, admitted that the high rate of false positives are a downside to the scan and can be stressful for patients. But she also noted that the screening improved survival rates by 20 percent for the patients who actually did have cancer.

Mark Varvares, MD, Director, Saint Louis University Cancer Center

May 26th, 2013




Mark Varvares, MD
Director, Saint Louis University Cancer Center


Undergraduate: University of Missouri, Columbia, Missouri
Medical School: Saint Louis University School of Medicine
St.Louis, MO
Internship: Northwestern Memorial Hospital
Chicago, IL
Residency: Harvard Medical School
Massachusetts Eye and Ear Infirmary, Boston, MA
Fellowship: Harvard Medical School, Boston, MA
Head and Neck Reconstructive Surgery
Board Certification
American Board of Otolaryngology
American Board of Facial Plastic and Reconstructive Surgery

Clinical Interests
Squamous cell carcinoma of the head and neck, free flap reconstruction of head and neck defects, skull base surgery, surgery of the parotid, thyroid and parathyroid glands, surgery of the larynx, cancer of the nose and paranasal sinuses

Research Interests
How the surgical pathology of head and neck tumor impacts survival, the histopathological response of head and neck cancer to chemoradiation, clinical outcomes as related to head and neck cancer therapy

Samantha Mixon is Changing thr Face of Lung Cancer

May 25th, 2013

ATLANTA — Samantha Mixon looks and feels great, but she is fighting stage four lung cancer and all the assumptions that people make about her disease.

“The first thing they ask is, ‘Did you smoke?’ It’s annoying at this point,” Mixon told 11Alive’s Jennifer Leslie.

She’s a non-smoker with no family history and only 33 years old.

She was diagnosed in November at Piedmont Henry Hospital after complaining of migraines. Turns out, she had a tumor that formed when the lung cancer metastasized to the brain.

“Telling my daughter was the hardest part about it,” Mixon said. “How do you tell her your mommy’s odds are not very good for five years, its one of the hardest things I’ve ever had to do.”

Mixon is part of a troubling trend, according to Piedmont Atlanta thoracic surgeon Dr. Saeid Khansarinia.
“We’re seeing more and more lung cancer in people who don’t smoke, especially women,” Dr. Khansarinia said.

Dr. Khansarinia said no one really knows why, but he said new targeted chemotherapy drugs are working well for younger, nonsmoking women.
“They seem to have much better success in controlling the disease and putting some of our patients even into remission,” he added.

Mixon and her 8-year-old daughter Karley still struggle with statistics that show a very low survival rate.
But the new drugs are making a difference, and Mixon is determined to do her part to raise awareness.

“It can happen to anyone,” she said. “It’s not a smoker’s disease anymore.”
For more information about lung cancer, Piedmont Healthcare has a list of symptoms, risk factors and treatment options.

Lung cancer is the leading cause of cancer death in both men and women.

Lung cancer usually does not cause symptoms when it first develops, but symptoms often become present after the tumor begins growing. A cough is the most common symptom of lung cancer.
Other symptoms include: constant chest pain, shortness of breath, wheezing, recurring lung infections, such as pneumonia or bronchitis, bloody or rust-colored sputum and hoarseness.

A tumor that presses on large blood vessels near the lung can cause swelling of the neck and face.

A tumor that presses on certain nerves near the lung can cause pain and weakness in the shoulder, arm, or hand.

Vanderbilt-Ingram Cancer Center

May 24th, 2013






William Pao, M.D., Ph.D.

Vanderbilt-Ingram Cancer Center

Dr. Pao is a physician-scientist with a special interest in thoracic oncology. Dr. Pao’s research focuses on identification of genes involved in the pathogenesis of lung tumors and stratifying tumors intoclinically relevant molecular subsets. Using information derived fromthese experiments, Dr.


Ph.D. – Yale University, 1998

M.D. – Yale University, 1990

Fellowship – Memorial Sloan-Kettering Cancer Center, 2005

Fellowship – Memorial Sloan-Kettering Cancer Center, 2004

Internship – New York Presbyterian Hospital, 2000

Residency – New York Presbyterian Hospital, 2000

Research Specialty

The Pao Laboratory aims to perform translational research in the area of solid tumor biology, using lung cancer as a paradigm. The overall goal is to develop molecularly-tailored treatments for patients with lung cancer.

Research Description

Lung cancer is the leading cause of cancer-related death in the U.S and worldwide. Most cases arise in former or current smokers, but about 10% of cases also occur in individuals who smoked less than 100 cigarettes in a lifetime (“never smokers”). Lung cancers are currently classified by histopathological techniques as either small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). In North America, adenocarcinoma (a type of NSCLC) is the most frequent type of histological tumor, accounting for 40% of all cases of lung cancer.

New “targeted” epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like gefitinib (Iressa) and erlotinib (Tarceva) have given us a window of opportunity to elucidate clinically relevant molecular subsets of lung adenocarcinomas. For example, clinical trials have shown that gefitinib has an overall response rate of 10% in American and European populations, and 28% in Japanese patients. Retrospective analyses suggested that gefitinib is most efficacious in “never smokers” with adenocarcinoma histology. Such findings can now be largely accounted for by research from our group and others showing the relatively high incidence of mutations in the gene encoding EGFR in these respective populations and the association of EGFR mutations with increased sensitivity to both gefitinib and erlotinib.

While EGFR mutations are common in tumors from never smokers, mutations in KRAS, which encodes a signaling molecule downstream of EGFR, more commonly occur in individuals with substantial cigarette use. Moreover, EGFR and KRAS mutations appear to be mutually exclusive, suggesting that EGFR and KRAS mutations within lung epithelia are equivalent in their tumorigenic effects. We found that mutations in KRAS are associated with primary resistance to these drugs. This suggests that pre-treatment mutational profiling of both EGFR and KRAS may help guide treatment decisions regarding the use of these agents.

Unfortunately, virtually all patients who initially respond to gefitinib and erlotinib eventually develop acquired resistance. We have shown that tumor cells from patients whose disease progresses after initial responses on therapy with these agents frequently harbor second-site mutations in EGFR. The predominant second mutation substitutes methionine for threonine at position 790 in EGFR, which is predicted to block binding of gefitinib and erlotinib to the ATP-binding pocket of the kinase. Interestingly, the T790M amino acid change is analogous to changes seen in other kinases targeted by a related kinase inhibitor, imatinib (Gleevec), in patients that develop acquired resistance to that drug. Using a genomic approach, we have also recently found that tumor samples from patients with acquired resistance to gefitinib or erlotinib harbor amplification of MET, which encodes another tyrosine kinase. MET amplification appears to occur independently of T790M mutations. Importantly, MET inhibitors are currently being developed in the clinic.

The Pao Laboratory is now focused on the following:

1)            Defining further molecular subsets of lung cancers, based primarily upon mutational profiling of the oncogenome in tumor samples.

2)            Elucidating other mechanisms of sensitivity and resistance to EGFR inhibitors in lung cancer. For example, we recently showed that in drug-sensitive EGFR mutant lung cancer cells, induction of BIM is essential for apoptosis triggered by.



Keasha Rutledge Draft

May 13th, 2013

Dance ~ Smile ~ Live

Dance ~ Smile ~ Live

Lakeasha (Keasha) Monique Rutledge Draft, 38, of Atlanta, Georgia departed this earth on Tuesday, December 27, 2011.

Born on May 13, 1973 to Tommy and Gail Rutledge in Anderson, South Carolina, she was always a shining star while she attended the Palmetto schools of Anderson District One, and graduated a year early with honors. Keasha was a faithful member of her family church New Prospect Baptist Church of Williamston, SC. Always active and ambitious, Keasha participated in many organizations from National Honor Society to earning the title of captain on the varsity cheerleading squad. She was known for her phenomenal dancing ability, although her track and field accomplishments were stellar also, as she placed first in the high jump at the state meet every year from seventh through twelfth grade. She still holds the school record for high jump. As a Clemson University student, she was a well-loved classmate, dancer for the Rallycats and was inducted into the Lambda Theta Chapter of Alpha Kappa Alpha Sorority, Inc. in the Spring of 1992. Keasha received her Bachelors of Science degree in Electrical Engineering from Clemson University in 1995. She began her career in engineering for Cutler-Hammer. Keasha was an NBA dancer and beloved teammate for the Charlotte Hornets Honeybees. She began working as a pharmaceutical sales representative for Sanofi-Aventis in Charlotte and transferred to Atlanta, Georgia where she worked until her illness transpired. On November 27, 2011, she married her long-time sweetheart, Christopher Draft.

Keasha leaves to cherish beautiful memories her loving husband, Chris Draft; parents, Tommy and Gail Rutledge; parents-in-law, Anthony and Rose Draft; maternal grandmother, Wilma Clement; paternal grandmother, Synola Rutledge; and a host of relatives and friends.

In honor of Keasha’s admirable vibrant spirit, celebrate each day, dance often, smile, laugh, and embrace life.

~MUAH. Peace.

Keasha Rutledge Draft–Changing the Face of Lung Cancer from TEAM DRAFT on Vimeo.